Boston Scientific to pay up to $24.3m for Israeli start-up

The identity of the buyer of medical device company SI Therapies has been revealed.

The identity of the buyer of SI Therapies has been revealed: US medical devices giant Boston Scientific (NYSE: BSX), which the past has acquired Israeli companies Remon Medical and Labcoat, and has invested in many Israeli biomed companies and funds.

Aran Research Development & Prototypes has published new details in its financials about the agreement it signed to sell the subsidiary (55%), from which it emerges that Boston Scientific paid $5.13 million in cash, and that the purchase price could reach $24.3 million if milestones are reached.

In November 2010, Aran reported that SI Therapies, which has developed a cardiology product, had been sold to a foreign company under a contract that would yield an immediate profit of $3.4 million. Aran will provide to Boston Scientific consultancy services in relation to the product, which could expand its revenue from the agreement. Aran did not disclose what the product was, but from previous reports from Boston Scientific it can be understood that it is a device for treating peripheral blocked arteries.

Aran Research Development & Prototypes has a market cap of NIS 37.7 million on the Tel Aviv Stock Exchange. The company engages in engineering development, mainly for other companies, and also invests in start-up ventures.

Published by Globes [online], Israel business news - - on April 4, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס